The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization
Authors:
Top Cited Papers
- 1 January 2014
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 7 (1) , 10-19
Abstract
No abstract availableKeywords
Funding Information
- Abbott Vascular
- Biotronik
This publication has 22 references indexed in Scilit:
- Vascular Hospitalization Rates and Costs in Patients With Peripheral Artery Disease in the United StatesCirculation: Cardiovascular Quality and Outcomes, 2010
- Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO StudyHeart, 2010
- Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal ArteryCirculation: Cardiovascular Interventions, 2010
- Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent RestenosisCirculation, 2009
- Inhibition of Restenosis in Femoropopliteal ArteriesCirculation, 2008
- Nitinol Stent Implantation Versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 cm in LengthCirculation, 2007
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Journal of Vascular Surgery, 2007
- Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon CatheterNew England Journal of Medicine, 2006
- Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of RestenosisCirculation, 2004
- Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary LesionsCirculation, 2004